OnKure Announces Encouraging Preliminary Safety, Tolerability, and Pharmacokinetic (PK) Data from its First-In-Human PIKture-01 Trial of OKI-219

-- OKI-219 is well-tolerated across all doses, and no dose interruptions, delays, reductions, or discontinuations were reported

-- Initial patient data show exposures of OKI-219 exceeding levels associated with robust antitumor activity in preclinical models

Read more at globenewswire.com